DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of DURECT (NASDAQ:DRRXGet Free Report) in a report released on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th.

View Our Latest Stock Analysis on DRRX

DURECT Price Performance

Shares of DRRX opened at $0.95 on Friday. DURECT has a one year low of $0.49 and a one year high of $1.88. The company’s fifty day moving average price is $1.11 and its 200 day moving average price is $1.32. The company has a market capitalization of $29.49 million, a PE ratio of -1.56 and a beta of 1.01.

Hedge Funds Weigh In On DURECT

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in DURECT by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 14,658 shares during the last quarter. Richmond Brothers Inc. raised its position in shares of DURECT by 39.5% during the second quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock valued at $1,383,000 after buying an additional 303,670 shares during the last quarter. Finally, International Assets Investment Management LLC lifted its stake in shares of DURECT by 41.3% in the second quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after buying an additional 6,300 shares during the period. Institutional investors own 28.03% of the company’s stock.

About DURECT

(Get Free Report)

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

Further Reading

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.